Listed

Nephros Inc: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Nov 5, 2020 and accepted by EDGAR at Nov 5, 2020, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-07-01 to 2020-09-30$2.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-01-01 to 2020-09-30$6.2mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-07-01 to 2020-09-30$896.0kus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2020-01-01 to 2020-09-30$2.6mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-07-01 to 2020-09-30$1.2mus-gaap:GrossProfit
Gross profit9 months2020-01-01 to 2020-09-30$3.6mus-gaap:GrossProfit
Research and development3 months2020-07-01 to 2020-09-30$751.0kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$2.1mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-07-01 to 2020-09-30$1.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2020-01-01 to 2020-09-30$5.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-07-01 to 2020-09-30−$932.0kus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30−$3.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-07-01 to 2020-09-30$22.0kus-gaap:InterestExpense
Interest expense9 months2020-01-01 to 2020-09-30$95.0kus-gaap:InterestExpense
Net income3 months2020-07-01 to 2020-09-30−$1.0mus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-30−$3.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-07-01 to 2020-09-30−$0.12us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2020-01-01 to 2020-09-30−$0.44us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2020-01-01 to 2020-09-30−$5.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$239.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-09-30$5.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$11.8mus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$15.2mus-gaap:Assets
Current liabilitiesAt period end2020-09-30$2.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-09-30$3.8mus-gaap:Liabilities
Long-term debtAt period end2020-09-30$652.0kus-gaap:LongTermDebt
Shareholders' equityAt period end2020-09-30$8.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-20-020593. Last ingested by Listed: Nov 13, 2026, 16:20 ET. Listed shows no prices and gives no investment advice.